bioAffinity initiates 2K-patient longitudinal study for CyPath Lung diagnostic

bioAffinity Technologies, Inc.

2,000-patient longitudinal study to evaluate CyPath Lung for early lung cancer detection in high-risk patients with nodules 6-29mm.
Study will include up to 20 sites, including a dozen VA medical centers and two large military hospitals.
Earlier trial showed 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in nodules <20mm.
Enrollment expected up to 18 months; patients followed up to 24 months or until definitive diagnosis.
Murtha Cancer Center Research Program provides support and funding for federal facilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.